2.80Open0.95Pre Close2 Volume2 Open Interest4.00Strike Price560.00Turnover0.00%IV6.98%PremiumNov 15, 2024Expiry Date2.71Intrinsic Value100Multiplier-1DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.47Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ALX Oncology Stock Discussion
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced tha...
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...
Please close above the 20
No comment yet